Sign In
Buy XGN
$4.54
-0.280 (-5.81%)
At Close: Jun 03, 2026
Exagen Inc. Announces Select Preliminary 2025 Financial Results
03:00pm, Sunday, 11'th Jan 2026
CARLSBAD, Calif., Jan. 11, 2026 (GLOBE NEWSWIRE) -- Exagen Inc. (Nasdaq: XGN), a leading provider of autoimmune testing, today announced select preliminary unaudited financial results for the fourth q
Exagen Inc. (NASDAQ:XGN) Given Consensus Rating of “Moderate Buy” by Analysts
01:20am, Tuesday, 25'th Nov 2025
Exagen Inc. (NASDAQ: XGN - Get Free Report) has earned a consensus recommendation of "Moderate Buy" from the nine analysts that are covering the company, MarketBeat.com reports. One investment analyst
Exagen Inc. to Participate in Fourth Quarter Investor Conferences
09:00am, Tuesday, 11'th Nov 2025
CARLSBAD, Calif., Nov. 11, 2025 (GLOBE NEWSWIRE) -- Exagen Inc. (Nasdaq: XGN), a leading provider of autoimmune testing, today announced that management will participate in the following upcoming inve
Exagen Inc. (XGN) Q3 2025 Earnings Call Transcript
03:56pm, Tuesday, 04'th Nov 2025
Exagen Inc. ( XGN ) Q3 2025 Earnings Call November 4, 2025 8:30 AM EST Company Participants Ryan Douglas - Investors Relations Officer John Aballi - CEO, President & Director Jeffrey Black - CFO & Cor
Exagen Inc. (XGN) Reports Q3 Loss, Tops Revenue Estimates
10:11am, Tuesday, 04'th Nov 2025
Exagen Inc. (XGN) came out with a quarterly loss of $0.19 per share versus the Zacks Consensus Estimate of a loss of $0.13. This compares to a loss of $0.28 per share a year ago.
Exagen Inc. Reports Strong Q3 2025 Results
08:00am, Tuesday, 04'th Nov 2025
CARLSBAD, Calif., Nov. 04, 2025 (GLOBE NEWSWIRE) -- Exagen Inc. (Nasdaq: XGN), a leading provider of autoimmune testing solutions, today reported financial results for the quarter ended September 30,
Exagen Inc. (NASDAQ:XGN) Receives Consensus Rating of “Moderate Buy” from Analysts
01:40am, Friday, 31'st Oct 2025
Shares of Exagen Inc. (NASDAQ: XGN - Get Free Report) have earned a consensus recommendation of "Moderate Buy" from the nine analysts that are presently covering the stock, MarketBeat.com reports. One
Exagen Announces Acceptance of Six Abstracts at 2025 American College of Rheumatology Convergence
09:15am, Thursday, 23'rd Oct 2025
CARLSBAD, Calif., Oct. 23, 2025 (GLOBE NEWSWIRE) -- Exagen Inc. (Nasdaq: XGN), a leading provider of autoimmune testing, announced today the acceptance of six abstracts at the 2025 American College of
Exagen Inc. to Announce Third Quarter 2025 Financial Results on November 4, 2025
04:05pm, Tuesday, 21'st Oct 2025
CARLSBAD, Calif., Oct. 21, 2025 (GLOBE NEWSWIRE) -- Exagen Inc. (Nasdaq: XGN), a leading provider of innovative autoimmune testing, will release financial results for the quarter ended September 30, 2
Exagen price target raised to $15 from $12 at KeyBanc
06:36am, Tuesday, 14'th Oct 2025
KeyBanc raised the firm's price target on Exagen to $15 from $12 and keeps an Overweight rating on the shares. The firm is raising its FY25 and FY26 estimates, as KeyBanc believes visibility on revenu
Exagen Inc. to Participate in Third Quarter Investor Conferences
04:05pm, Wednesday, 06'th Aug 2025
CARLSBAD, Calif., Aug. 06, 2025 (GLOBE NEWSWIRE) -- Exagen Inc. (Nasdaq: XGN), a leading provider of innovative autoimmune testing, today announced that management will participate in the following
Exagen Inc. (XGN) Q2 2025 Earnings Call Transcript
03:09pm, Tuesday, 29'th Jul 2025
Exagen Inc. (NASDAQ:XGN ) Q2 2025 Earnings Conference Call July 29, 2025 8:30 AM ET Company Participants Jeffrey G. Black - CFO & Corporate Secretary John Aballi - CEO, President & Director Ryan Dougl
Exagen Q2 Revenue Jumps 14 Percent
11:51am, Tuesday, 29'th Jul 2025
Exagen Q2 Revenue Jumps 14 Percent
Exagen Inc. (XGN) Reports Q2 Loss, Beats Revenue Estimates
10:10am, Tuesday, 29'th Jul 2025
Exagen Inc. (XGN) came out with a quarterly loss of $0.18 per share in line with the Zacks Consensus Estimate. This compares to a loss of $0.16 per share a year ago.
Exagen Inc. Reports Strong Q2 2025 Results
08:00am, Tuesday, 29'th Jul 2025
CARLSBAD, Calif., July 29, 2025 (GLOBE NEWSWIRE) -- Exagen Inc. (Nasdaq: XGN), a leading provider of autoimmune testing solutions, today reported financial results for the quarter ended June 30, 2025
